ストックスクリーナーアプリを入手
16.62
4.87%
-0.85
Summit Therapeutics Inc (SMMT) 最新ニュース
Bernstein initiates coverage of Summit Therapeutics (SMMT) with underperform recommendation - MSN
HC Wainwright & Co. downgrades Summit Therapeutics (SMMT) - MSN
SMMT Initiates Coverage On Summit Therapeutics -- Rating Underpe - GuruFocus
Summit Therapeutics (SMMT) Faces Downgrade Amidst Competitive Pr - GuruFocus
Summit Therapeutics (SMMT) Downgraded to Neutral Amid Competitiv - GuruFocus
SMMT Downgraded by HC Wainwright & Co. -- Rating Changes to Neut - GuruFocus
Summit Therapeutics Shares Fall After HC Wainwright Downgrade - marketscreener.com
This Summit Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For FridayCentene (NY - Benzinga
Summit downgraded at H.C. Wainwright after Merck data for sac-TMT - Seeking Alpha
Summit Therapeutics Price Target Announced at $7.70/Share by Bernstein - Moomoo
Why is Summit Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Here's Why You Should Add SMMT Stock to Your Portfolio Now - Yahoo Finance
Cantor Fitzgerald reiterates Overweight on Summit Therapeutics stock By Investing.com - Investing.com Canada
S&P 500 Futures Climb In Premarket Trading; WR Berkley, Summit Therapeutics Lag - Moomoo
H.C. Wainwright downgrades Summit Therapeutics stock rating to neutral By Investing.com - Investing.com Canada
Bernstein Initiates Summit Therapeutics at Underperform - Moomoo
HC Wainwright Downgrades Summit Therapeutics to Neutral From Buy - Moomoo
Summit Therapeutics (SMMT) Faces Scrutiny with Underperform Rati - GuruFocus
Bernstein downgrades Summit Therapeutics stock rating on trial concerns By Investing.com - Investing.com Canada
Summit Therapeutics Inc.Common Stock (NQ: SMMT - The Chronicle-Journal
Cancer Stocks That Are Advancing the Future of Oncology Care - Yahoo! Finance Canada
Summit Therapeutics Inc. (SMMT) Stock Analysis: Healthcare Innovator with Potential 74% Upside - DirectorsTalk Interviews
(SMMT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
A Look At Summit Therapeutics (SMMT) Valuation After HARMONi-3 Trial Risk Highlighted By Analyst Commentary - Yahoo Finance
H.C. Wainwright Reduced its Price Goal on Summit Therapeutics Inc. (SMMT) - Insider Monkey
SMMT Stock Chart | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Summit Therapeutics falls after update on Akeso-partnered lung cancer trial - MSN
8 Most Promising Biotech Stocks to Buy Now - Insider Monkey
SMMT Technical Analysis | Trend, Signals & Chart Patterns | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Summit Therapeutics (SMMT) Is Down 20.1% After Q1 2026 Net Loss Widens Sharply - simplywall.st
Summit Therapeutics Inc (SMMT) News, Articles, Events & Latest Updates - Stocktwits
Q2 EPS Estimate for Summit Therapeutics Boosted by Analyst - MarketBeat
Q2 Earnings Forecast for SMMT Issued By HC Wainwright - MarketBeat
How (SMMT) Movements Inform Risk Allocation Models - Stock Traders Daily
JPM: AKESO (09926.HK) Lung Cancer Trial Final Analysis Likely to Meet Target; Rating Overweight - AASTOCKS.com
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III - BioWorld News
SMMT Q1 Loss Narrower Than Expected, Stock Down on Ivonescimab Setback - Yahoo Finance
Summit Therapeutics: More Uncertainty Heading Into The ASCO Plenary (NASDAQ:SMMT) - Seeking Alpha
Investigation into Summit Therapeutics by Johnson Fistel - Intellectia AI
Summit Therapeutics Inc. Shareholders Are Encouraged to - GlobeNewswire
SMMT Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
H.C. Wainwright cuts Summit Therapeutics stock price target on trial risk - Investing.com Canada
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Cuts Target Price to $23 - Moomoo
We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely - Yahoo Finance
Summit Therapeutics Inc. (SMMT) Stock Analysis: Promising 91% Upside in the Biotech Sector - DirectorsTalk Interviews
Biopharmaceutical News: Summit Therapeutics Stock Plummets After Trial Analysis Misstep - geneonline.com
Analysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Summit Therapeutics (SMMT) - The Globe and Mail
SMMT Plunges As Summit Therapeutics Stock Suffers 27% Selloff - StocksToTrade
Summit Therapeutics Stock Plunges As Selling Pressure Intensifies - timothysykes.com
Roblox, Spotify, And Robinhood Are Among Top 10 Large-Cap Losers Last Week (April 27-May 1): Are The Others In Your Portfolio? - Benzinga
Summit Therapeutics (SMMT) Receives a Rating Update from a Top Analyst - The Globe and Mail
Summit Therapeutics Flags Significant Going-Concern Risk Amid Cash Shortfall and Uncertain Financing - The Globe and Mail
Summit Therapeutics (SMMT) Is Down 27.0% After HARMONi-6 OS Plenary, BLA Progress And Wider LossesHas The Bull Case Changed? - simplywall.st
This is why Summit Therapeutics (SMMT) is one of the Best Stocks to buy in a Rising Market - Yahoo Finance
TD Cowen Maintains Summit Therapeutics(SMMT.US) With Buy Rating - Moomoo
Summit Therapeutics (NASDAQ:SMMT) Issues Earnings Results - MarketBeat
2.98%
1.33%
大文字化:
|
ボリューム (24 時間):